Human Immunodeficiency Virus Type 1 (HIV‐1) gp120–Specific Antibodies in Neonates Receiving an HIV‐1 Recombinant gp120 Vaccine
Elizabeth J. McFarland(University of Colorado Anschutz Medical Campus), Robert A. Livingston, Yvonne J. Bryson(Oklahoma State University Center for Health Sciences), Stephen A. Spector(University of California San Diego), Anne‐Marie Duliège(Sunesis (United States)), Lisa M. Frenkel(Infectious Disease Research Institute), Sandra Burchett(Harvard University), Coleen K. Cunningham(Duke Medical Center), Terry Fenton(Harvard University), Katherine Luzuriaga(University of Massachusetts Chan Medical School), James McNamara(National Institute of Allergy and Infectious Diseases), Pearl Samson(Harvard University), Lynne Mofenson(Elizabeth Glaser Pediatric AIDS Foundation), Minhee Kang(Cancer Research And Biostatistics), Eleanor Jiménez(University of Miami), Diane W. Wara(University of California, San Francisco), Francis Gigliotti(University of Rochester Medicine), Faruk Sinangil(Global Solutions for Infectious Diseases), William Borkowsky(New York University), Ram Yogev(Northwestern University)
Cited by 62
Related Papers
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
|New England Journal of Medicine|2012|3.3k
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
|The Lancet|1999|1.7k
Combination Antiretroviral Strategies for the Treatment of Pregnant HIV-1–Infected Women and Prevention of Perinatal HIV-1 Transmission
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2002|896